Association Between Maternal Intrapartum Pethidine Exposure and Respiratory Depression in Late-Preterm Newborns
Association Between Maternal Intrapartum Pethidine Exposure and Neonatal Respiratory Depression in Late-Preterm Newborns: A Multicenter Prospective Cohort Study
This study aims to investigate whether exposure to pethidine during labor is associated with breathing difficulties in late-preterm newborns. Late-preterm babies are those born between 34 weeks and 36 weeks plus 6 days of pregnancy. Although they are close to full term, they may still have an increased risk of breathing problems after birth.
The study will be conducted at two hospitals: Zagazig University Hospitals in Egypt and Royale Hayat Hospital in Kuwait. It will include approximately 320 mothers and their newborn babies.
The researchers will prospectively observe two groups of mothers receiving combined spinal-epidural (CSE) analgesia during labor. The first group will include mothers who receive pethidine in addition to CSE analgesia as part of their clinical care. The second group will include mothers who receive CSE analgesia without pethidine. The decision to administer pethidine will remain entirely with the treating medical team and will not be determined by the research study.
The main purpose is to compare the occurrence of clinically significant breathing difficulties in newborns during the first 24 hours after birth. The study will also assess the need for newborn resuscitation, oxygen therapy, respiratory support, admission to the neonatal intensive care unit, feeding difficulties, and other neonatal outcomes. Maternal outcomes will also be evaluated.
The findings may improve understanding of the association between maternal intrapartum pethidine exposure and neonatal health, particularly when pethidine is used as an adjunct during labor to facilitate cervical effacement, ripening, and dilatation alongside combined spinal-epidural analgesia. The results may help clarify the potential neonatal respiratory risks associated with this practice, support evidence-based decisions regarding intrapartum pain management and cervical preparation, and contribute to improving maternal and neonatal safety.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Late-preterm infants, defined as newborns delivered between 34+0 and 36+6 weeks of gestation, have a higher risk of neonatal complications than term infants because of their relative physiological immaturity. Respiratory morbidity is particularly important in this population, as these newborns may experience respiratory difficulties requiring additional assessment, monitoring, or respiratory support after birth.
Pethidine (meperidine) is an opioid medication used in obstetric practice during labor. In addition to its analgesic properties, it may be administered as an adjunct during labor in certain clinical settings to facilitate cervical effacement and dilatation. Maternal intrapartum administration of pethidine results in placental transfer and fetal exposure. Because opioids can depress the central nervous system and respiratory drive, exposure close to delivery may potentially affect neonatal respiratory adaptation after birth.
The potential effects of maternal pethidine exposure are particularly relevant in late-preterm newborns, whose respiratory and neurological systems are not yet fully mature. However, the relationship between intrapartum pethidine exposure and clinically significant neonatal respiratory depression in this population requires further investigation, particularly in the context of contemporary obstetric analgesia practices.
This study will investigate the association between maternal intrapartum pethidine exposure and neonatal respiratory outcomes among late-preterm newborns delivered in two different clinical settings. The study will focus on mothers receiving combined epidural analgesia, comparing those who also receive pethidine as part of their routine clinical care with those who receive combined epidural analgesia without pethidine.
The research will follow a prospective observational cohort design. Maternal medication exposure and relevant obstetric characteristics will be documented, together with neonatal clinical assessments and outcomes. The administration of pethidine and the selection of analgesic techniques will remain entirely at the discretion of the treating obstetric and anesthetic teams. The research will not introduce, assign, or modify any medication or clinical intervention.
By examining the association between maternal pethidine exposure, obstetric characteristics, and neonatal outcomes, this study aims to provide clinically relevant evidence regarding the potential respiratory effects of intrapartum opioid exposure in late-preterm newborns. The findings may help inform evidence-based obstetric practices concerning the adjunctive use of pethidine during cervical effacement and dilatation, alongside maternal analgesia, while supporting appropriate neonatal monitoring and early recognition of respiratory complications.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Mustafa Alfiki, MSc, PharmD
- 電話番号:0096555021180
- メール:mustafa.alfiki@gmail.com
研究連絡先のバックアップ
- 名前:Dr. Sarah Nafea, PhD, MSc
- 電話番号:00201068289698
- メール:Drsarahsabry511@gmail.com
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
late-preterm newborns delivered between 34+0 and 36+6 weeks of gestation. The study will include 320 newborns divided into two cohorts: 160 newborns exposed to maternal intrapartum pethidine alongside combined spinal-epidural analgesia and 160 newborns whose mothers received combined spinal-epidural analgesia without pethidine. Maternal clinical characteristics and intrapartum analgesic exposure will also be documented to assess their association with neonatal respiratory outcomes.
説明
Inclusion Criteria:
- Gestational age at delivery between 34+0 and 36+6 weeks.
- Maternal receipt of epidural analgesia during the index labor.
- Sufficient maternal medication and neonatal outcome documentation.
Exclusion Criteria:
- Congenital malformations expected to affect respiratory drive, airway patency, or cardiopulmonary adaptation
- Missing or unreliable maternal medication records that prevent exposure classification.
- Insufficient documentation to determine the primary outcome.
- Additional systemic opioid exposure that prevents meaningful classification according to the prespecified protocol.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Late-Preterm Newborns Exposed to Maternal Intrapartum Pethidine
160 late-preterm newborns (34+0 to 36+6 weeks of gestation) born to mothers who received intrapartum pethidine (meperidine), administered as part of routine clinical care at a planned dose of 50 mg administered via intramuscular (IM) or intravenous (IV) injection alongside combined spinal-epidural analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements. |
Maternal intrapartum exposure to pethidine (meperidine), administered as part of routine clinical care at a planned dose of 50 mg administered via intramuscular (IM) or intravenous (IV) injection to facilitate cervical effacement and dilatation alongside combined spinal-epidural analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements. Pethidine administration is determined independently by the treating clinical team based on the mother's clinical condition and cervical assessment, and is not assigned or controlled by study investigators. The precise dose, route, cumulative amount, and timing/interval from administration to delivery will be prospectively documented to evaluate their association with neonatal respiratory outcomes in late-preterm newborns (34+0 to 36+6 weeks of gestation).
他の名前:
|
|
Late-Preterm Newborns Without Maternal Intrapartum Pethidine Exposure
160 late-preterm newborns (34+0 to 36+6 weeks of gestation) born to mothers who received combined spinal-epidural (CSE) analgesia using bupivacaine and fentanyl, administered via the intrathecal and epidural route according to the institutional anesthesia protocol and individual clinical requirements without intrapartum pethidine exposure. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of Clinically Significant Neonatal Respiratory Depression Within 24 Hours After Birth
時間枠:From birth through the first 24 hours of life
|
Clinically significant neonatal respiratory depression is defined as apnea, gasping, or inadequate respiratory effort requiring active resuscitation or respiratory intervention beyond routine initial newborn care. This includes the need for positive-pressure ventilation (PPV), or recurrent apnea or persistent inadequate respiratory effort requiring escalation of respiratory support. The incidence will be calculated as the proportion of newborns experiencing at least one qualifying episode within the first 24 hours after birth. The association between maternal intrapartum pethidine exposure and this outcome will be assessed. Results will be reported as the number of affected newborns divided by the total number of newborns in each study group (n/N), and expressed as a percentage. Unit of Measure: Number of participants (newborns) experiencing clinically significant neonatal respiratory depression. |
From birth through the first 24 hours of life
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Neonatal Resuscitation at Birth
時間枠:At birth, during initial neonatal resuscitation
|
The need for active neonatal resuscitation beyond routine initial newborn care will be recorded, including positive-pressure ventilation (PPV) and other advanced resuscitation interventions, if required. The proportion of newborns requiring resuscitation will be calculated for each study group. Unit of Measurement: Number of participants (newborns) requiring active resuscitation. |
At birth, during initial neonatal resuscitation
|
|
Need for Neonatal Respiratory Support
時間枠:From birth through the first 24 hours of life
|
The requirement for respiratory support beyond routine initial newborn care will be recorded, including supplemental oxygen, continuous positive airway pressure (CPAP), non-invasive ventilation, and mechanical ventilation. The highest level of respiratory support required by each newborn during the assessment period will be documented. Unit of Measurement: Number of participants (newborns) requiring respiratory support. |
From birth through the first 24 hours of life
|
|
Association Between the Pethidine-to-Delivery Interval and Neonatal Respiratory Depression
時間枠:From the maternal pethidine administration until delivery, with neonatal respiratory depression assessed from birth through the first 24 hours of life.
|
The association between the time interval from the maternal intrapartum pethidine administration to delivery and the occurrence of clinically significant neonatal respiratory depression will be evaluated. The interval will be calculated from the time of the last pethidine dose to the time of birth. The incidence of neonatal respiratory depression within the first 24 hours after birth will be analyzed in relation to this interval. Unit of Measurement: Time interval (minutes or hours) between the maternal pethidine dose and delivery; number of newborns experiencing clinically significant respiratory depression. |
From the maternal pethidine administration until delivery, with neonatal respiratory depression assessed from birth through the first 24 hours of life.
|
|
Apgar Scores
時間枠:At 1 and 5 minutes after birth
|
Neonatal Apgar scores will be recorded at 1 and 5 minutes after birth. Each assessment will include heart rate, respiratory effort, muscle tone, reflex irritability, and skin color, with a total score ranging from 0 to 10 at each assessment. Unit of Measurement: Apgar score (0-10). |
At 1 and 5 minutes after birth
|
|
Neonatal Blood pH
時間枠:At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
Neonatal blood pH will be assessed using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal acid-base status. Results from both sampling time points will be recorded separately. Unit of Measurement: pH (unitless). |
At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
|
Neonatal Partial Pressure of Carbon Dioxide (PaCO₂)
時間枠:At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
Neonatal partial pressure of carbon dioxide (PaCO₂) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal ventilation status. Results from both sampling time points will be recorded separately. Unit of Measurement: mmHg. |
At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
|
Neonatal Partial Pressure of Oxygen (PaO₂)
時間枠:At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
Neonatal partial pressure of oxygen (PaO₂) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to assess neonatal oxygenation status. Results from both sampling time points will be recorded separately. Unit of Measurement: mmHg. |
At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
|
Neonatal Bicarbonate Concentration (HCO₃-)
時間枠:At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
Neonatal bicarbonate concentration (HCO₃-) will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to evaluate neonatal metabolic acid-base status. Results from both sampling time points will be recorded separately. Unit of Measurement: mmol/L. |
At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
|
Neonatal Blood Lactate Concentration
時間枠:At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
Neonatal blood lactate concentration will be measured using umbilical cord blood gas analysis at birth and neonatal blood gas analysis approximately 2 hours after birth to assess metabolic status and identify evidence of tissue hypoperfusion. Results from both sampling time points will be recorded separately. Unit of Measurement: mmol/L. |
At birth (umbilical cord blood) and approximately 2 hours after birth (neonatal blood gas)
|
|
Neonatal Lung Ultrasound Score
時間枠:Within the first 24 hours after birth
|
Neonatal lung aeration will be assessed using a standardized six-region lung ultrasound examination. Each region will be scored from 0 to 3, producing a total lung ultrasound score ranging from 0 to 18, with higher scores indicating greater lung aeration impairment. Lung ultrasound findings will be evaluated to identify physiological transitional lung patterns and abnormalities suggestive of pulmonary pathology, including retained lung fluid and consolidation, helping to identify alternative or coexisting pulmonary causes of neonatal respiratory distress. Unit of Measurement: Lung ultrasound score (0-18). |
Within the first 24 hours after birth
|
|
Neonatal Feeding Difficulties
時間枠:From birth through the first 24 hours of life
|
The occurrence of neonatal feeding difficulties will be assessed, including poor sucking, impaired coordination of sucking and swallowing, and feeding intolerance. The need for feeding assistance will also be documented. The proportion of newborns experiencing feeding difficulties will be calculated. Unit of Measurement: Number of participants (newborns) experiencing feeding difficulties. |
From birth through the first 24 hours of life
|
|
Neonatal Intensive Care Unit (NICU) Admission
時間枠:From birth through the first 24 hours of life
|
The number and proportion of newborns requiring admission to the neonatal intensive care unit (NICU) will be recorded. The primary clinical indication for NICU admission, including respiratory or other neonatal complications, will be documented at the time of admission. Unit of Measurement: Number of participants (newborns) admitted to the NICU. |
From birth through the first 24 hours of life
|
|
Maternal Pain Intensity During Labour
時間枠:Within the first 24 hours after delivery, covering the mother's overall experience of labour pain from the onset of labour until delivery.
|
Maternal pain intensity and the mother's overall experience of labour pain will be assessed in both study groups using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Each mother will be asked to provide an overall rating of the pain experienced during labour. The scores will be compared between the pethidine-exposed and unexposed groups. Unit of Measurement: Numeric Rating Scale score (0-10). |
Within the first 24 hours after delivery, covering the mother's overall experience of labour pain from the onset of labour until delivery.
|
|
Duration of Active Labour and Labour Progression
時間枠:From pethidine administration until delivery
|
The duration of active labour following intrapartum pethidine administration will be assessed from the time of pethidine administration until delivery. Labour progression will be evaluated by documenting cervical dilatation (cm) and cervical effacement (%) at subsequent obstetric examinations following pethidine administration until delivery. The association between maternal pethidine exposure and labour progression will be assessed. Unit of Measurement: Time from pethidine administration to delivery (hours); cervical dilatation (cm); cervical effacement (%). |
From pethidine administration until delivery
|
|
Maternal Adverse Effects Associated With Intrapartum Pethidine Exposure
時間枠:From pethidine administration until delivery
|
The occurrence of maternal adverse effects associated with intrapartum pethidine administration will be monitored and documented. Potential adverse effects include nausea, vomiting, dizziness, sedation, pruritus, hypotension, and respiratory depression. The type, occurrence, and any required clinical management of adverse effects will be recorded. The incidence of maternal adverse effects will be compared between the pethidine-exposed and unexposed study groups. Unit of Measurement: Number of participants experiencing at least one maternal adverse effect. |
From pethidine administration until delivery
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- スタディチェア:Dr. Noha Nassar, PhD, MSc、Faculty of Pharmacy, Cairo University, Egypt
- スタディディレクター:Dr. Sarah Nafea, PhD, MSc、Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Egypt
- スタディディレクター:Dr. Mahmoud Negm, PhD, MBBS、Faculty of Medicine, Zagazig University
- スタディディレクター:Dr. Nora Abdel Rasheed, PhD, MSc、Faculty of Pharmacy, Cairo University, Egypt
- 主任研究者:Mustafa Alfiki, MSc, PharmD、Faculty of Pharmacy, Cairo University, Egypt; Royale Hayat Hospital, Kuwait
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
- 硬膜外鎮痛
- 子宮頸部の消失
- メペリジン
- 新生児転帰
- ペチジン
- 子宮頸部の成熟
- 母体鎮痛
- 新生児呼吸抑制
- 前向き観察コホート研究
- 子宮頸管拡張
- Maternal Pethidine Exposure
- Intrapartum Opioid Exposure
- Neonatal Respiratory Morbidity
- Late-Preterm Infants
- Late-Preterm Birth
- Combined Spinal-Epidural Analgesia
- Cervical Maturation
- Labor Progression
- Neonatal Respiratory Outcomes
- Pethidine Exposure Before Delivery
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- RHH-MRA-2026-006
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。